# OnCo record denileukin-diftitox (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/denileukin-diftitox/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "denileukin-diftitox" ;
  schema:name "Denileukin diftitox"@en ;
  schema:alternateName "Ontak (1999 to 2014)"@en, "E7777"@en, "Lymphir" ;
  schema:description "Denileukin diftitox (Lymphir) is an infusion that uses the interleukin-2 signal as a homing device to deliver a bacterial toxin into cutaneous T-cell lymphoma cells. It was withdrawn in 2014 and returned in an improved form in 2024."@en ;
  schema:url <https://onco.cc/drugs/denileukin-diftitox/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Denileukin_diftitox> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=denileukin%20diftitox>, <https://www.cancer.gov/about-cancer/treatment/drugs/denileukindiftitox-cxdl> ;
  onco:status "approved" ;
  onco:tag "nci-list" ;
  onco:modality "IL-2 receptor-directed cytotoxin (fusion protein)" ;
  onco:approval "US 1999: Persistent or recurrent CD25-positive CTCL (Ontak; withdrawn 2014)", "US 2024: Relapsed or refractory stage I to III CTCL after at least one systemic therapy (Lymphir)" ;
  onco:acceleratedApproval "US 1999-02-05: Persistent or recurrent cutaneous T-cell lymphoma expressing the CD25 component of IL-2 receptor" ;
  onco:acceleratedApprovalConfirmed "US 2008-10-15: Persistent or recurrent cutaneous T-cell lymphoma expressing the CD25 component of IL-2 receptor" ;
  onco:targets <https://onco.cc/targets/cd25/> ;
  onco:companies <https://onco.cc/companies/citius-pharmaceuticals/>, <https://onco.cc/companies/eisai/> ;
  onco:trials <https://onco.cc/trials/nct01127451/>, <https://onco.cc/trials/nct00299689/>, <https://onco.cc/trials/nct00880360/> .